PwC Pharma & Life Sciences Webinar: COVID-19 impact on the ITX and regulatory DNA – Thursday 28. May 2020, 10:30 CEST

As the COVID-19 situation develops, tax and regulatory specialists within the pharmaceutical & life sciences industry are increasingly facing complex challenges. Efficient and pragmatic solutions have to be realised, with fewer resources, in line with the changing local legislation.

The exchange of information is the best practice in this industry to support and inspire you in your daily business.

In light of that, we would like to invite you to our Pharma & Life Science webinar where we and other industry professionals will be discussing the impact of COVID-19 on the ITX and regulatory DNA on the pharma and life science industry.

We will be talking about VAT, regulatory and export control topics in the pharmaceutical and life science business concentrating on Risks and Opportunities, which impact national and international sale of drugs, precision medicines, clinical trials and technology.

We look forward to welcoming you to our webinar.

Date
Thursday 28. May 2020

Time
10.30am – 11.15am (CEST)

Speakers
Dr. Sandra Ragaz-Fumia, Partner, Leader Pharma & Life Science VAT, PwC Switzerland
Christine Frankenberger, Manager, Manager, Export Controls, Customs & International Trade, PwC Switzerland

Agenda
10:30 –
Welcome
10:35 – Required VAT documentation for Clinical Trials in Europe during COVID-19
10:45 – COVID-19 and impact on EU GMP Annex 21 for the sale of pharmaceuticals
10:55 – Precision medicines and COVID-19 – VAT and export control consideration
11:05 – Q&A Session and Closing

Register (free of charge)
Register here >

Happy to welcome you personally at the webex.

Best regards and see you there, Sandra